News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1โ€“36
Matches
40
Sources here
16
Companies here
1
Search results Stored financial headlines

Active search

40 matching headlines

Ticker or company: OPKMain companies and provider mentions
Clear
Latest

finance.yahoo.com Earnings

Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?

It has been about a month since the last earnings report for OPKO Health (OPK). Shares have lost about 9.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is OPKO Health due for a breakout? Before we dive into how investors and analysts have โ€ฆ

Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Read at finance.yahoo.com
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
Just inNext headlines
TradingView Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

Here's Why You Should Retain OPK Stock in Your Portfolio for Now

OPKO Health, Inc. OPK is well-positioned for growth in the coming quarters, supported by the potential of RAYALDEE. Optimism surrounding the stock is driven by RAYALDEE's strong performance, strategic partnerships, BioReference restructuring and multiple pipeline catalysts. However, overdependence on RAYALDEE, early-stage clinical development risks โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

finance.yahoo.com Deals and strategy Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

OPKO Health Secures $125 Million Financing Against Mazdutide Royalties

OPKO Health OPK expanded its strategic financing relationship with HealthCare Royalty (HCRx) by issuing $125 million of senior secured notes backed by its royalty interests from the mazdutide license agreement with Eli Lilly. The transaction provides OPKO with additional non-dilutive capital while allowing it โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Market update Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests

OPKO Health, Inc. Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside MIAMI, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the expansion of its financing relationship with HealthCare Royalty, a business โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
nasdaq.com Earnings Provider-linked mention ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

Entera Q2 Loss Widens, FDA Backs EB613 For Phase 3 Osteoporosis Trial, Expects Data In Q2 Of FY28

(RTTNews) - Entera Bio Ltd. (ENTX), a clinical-stage biopharmaceutical company, reported a wider net loss for the second quarter, on surge in financial expense and more than double the growth in research and development expenses. Further, the company plans to initiate Phase 3 study โ€ฆ

OPK mentioned
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

OPKO Health (OPK) Is Up 36.0% After Narrower Q2 Loss And New 2026 Guidance Has The Bull Case Changed?

OPKO Health, Inc. reported its second-quarter 2026 results on July 27, 2026, with revenue of US$163.58 million and a net loss of US$8.42 million, alongside updated guidance calling for total revenue of US$131 million to US$142 million for the third quarter and US$560 million โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
nasdaq.com Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

Why Opko Health Stock Surged by 33% on Tuesday

Key Points Investors were also cheered by a substantial narrowing of the company's net loss. Ditto for the raised full-year revenue guidance.10 stocks we like better than Opko Health โ€บ Opko Health(NASDAQ: OPK) was one of the healthier stocks on the exchange Tuesday. Its โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
seekingalpha.com Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

Opko outlines $560M-$585M 2026 revenue guidance while planning MDX3001 clinical start by end of 2026 or early 2027

Earnings Call Insights: OPKO Health (OPK) Q2 2026 MANAGEMENT VIEW * "During the second quarter, we made meaningful progress in improving operating efficiency and profitability and in advancing our product pipeline," said Dr. Phillip Frost (Chairman of the Board & CEO), while adding, "ModeX โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics

OPKO Health (OPK) reported $163.5 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 4.3%. EPS of -$0.01 for the same period compares to -$0.19 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $131.13 โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

OPKO Health, Inc. Conference Call to Begin Today at 4:30 p.m. ET MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today reports business โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
seekingalpha.com Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

OPKO Health Q2 2026 Earnings Preview

* OPKO Health (OPK [https://seekingalpha.com/symbol/OPK]) is scheduled to announce Q2 earnings results on Monday, July 27th, after market close. * The consensus EPS estimate is -$0.08, [https://seekingalpha.com/symbol/OPK/earnings/estimates] and the consensus revenue estimate is $131.23M (-16.3% Y/Y). MORE ON OPKO HEALTH * OPKO Health, Inc. โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026
finance.yahoo.com Earnings Main company ๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026

OPKO Health, Inc. MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established global markets, today announced that it will report operating and financial results for the โ€ฆ

OPK main company
Sharemaestro market context Trend signal active 52 weeks -6.7% OPK stored weekly price path from 29 Aug 2025 to 21 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context